Farxiga® (dapagliflozin) – New indication
October 21, 2019 - AstraZeneca announced the FDA approval of Farxiga (dapagliflozin), to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Top